Role of Transforming Growth Factor-β in Skeletal Muscle Fibrosis: A Review

Ahmed Ismaeel 1, Jeong-Su Kim 1, Jeffrey S. Kirk 2, Robert S. Smith 3, William T. Bohannon 3 and Panagiotis Koutakis 1,∗

1 Department of Nutrition, Food & Exercise Sciences, Florida State University, Tallahassee, FL 32304, USA; aii18@my.fsu.edu (A.I.); jkim6@fsu.edu (J.-S.K.)
2 Department of Surgery, Capital Regional Medical Center, Tallahassee, FL 32308, USA; jeffrey.kirk@hcahealthcare.com
3 Department of Surgery, Baylor Scott and White Hospital, Temple, TX 76508, USA; robert.smith@bswhealth.org (R.S.S.); william.bohannon@bswhealth.org (W.T.B.)
* Correspondence: pkoutakis@fsu.edu; Tel.: 850-644-1829

Received: 16 April 2019; Accepted: 15 May 2019; Published: 17 May 2019

Abstract: Transforming growth factor-beta (TGF-β) isoforms are cytokines involved in a variety of cellular processes, including myofiber repair and regulation of connective tissue formation. Activation of the TGF-β pathway contributes to pathologic fibrosis in most organs. Here, we have focused on examining the evidence demonstrating the involvement of TGF-β in the fibrosis of skeletal muscle particularly. The TGF-β pathway plays a role in different skeletal muscle myopathies, and TGF-β signaling is highly induced in these diseases. In this review, we discuss different molecular mechanisms of TGF-β-mediated skeletal muscle fibrosis and highlight different TGF-β-targeted treatments that target these relevant pathways.

Keywords: TGF-β; fibrosis; skeletal muscle; myopathy

1. Introduction

Transforming growth factor-beta (TGF-β) is a multifunctional cytokine that includes the isoforms TGF-β 1-3 [1]. The TGF-β signaling pathway is involved in various cellular processes and functions including cell growth, differentiation, and apoptosis [1]. TGF-β also regulates the phenotype and function of fibroblasts and plays a role in myofibroblast transdifferentiation [2,3]. TGF-β functions to promote extracellular matrix (ECM) preservation by enhancing matrix protein synthesis, promoting expression of ECM and profibrotic genes such as type I collagen and connective tissue growth factor (CTGF), and suppressing the activity of ECM degradation proteins such as matrix metalloproteinases (MMPs) [2,3]. Activation of the TGF-β signaling pathway initiates collagen accumulation that is important for wound repair, but certain pathological triggers such as ischemia reperfusion injury (IRI), can lead to enhanced ECM strengthening and progressive fibrosis, which has earned TGF-β the title of “the master regulator of fibrosis” [4,5]. In fact, TGF-β plays a role in the pathogenesis of fibrosis in most organs, including the lung, liver, kidney, heart, and skeletal muscle and is implicated in several diseases and syndromes [6].

Skeletal muscle fibrosis severely impairs muscle function via reduced motile and contractile function. Skeletal muscle fibrosis is characterized by increased area of the ECM in muscle cross-sections, and as a result of enhanced collagen deposition, increased muscle stiffness as well as contracture limits function and mobility [7]. In addition, fibrosis also limits the amount of muscle that is available as a target for therapy and repair. Inability to restore muscle function can lead to disease progression in skeletal muscle myopathies [8].
The purpose of this review is to present the evidence for the involvement of TGF-β in skeletal muscle fibrosis and to explore the molecular mechanisms behind TGF-β’s pro-fibrotic actions in skeletal muscle. We also discuss the role of TGF-β in muscular diseases and discuss potential anti-fibrotic treatments that target the TGF-β pathway.

2. TGF-β Signaling Pathway

The TGF-β superfamily consists of over 50 members that are structurally related, falling into one of three subfamilies: TGF-β, bone morphogenic protein (BMP), and activin [9]. Of all the ligands, TGF-β1 and myostatin are the most implicated in skeletal muscle. Myostatin, a myokine and secreted growth differentiation factor, is a member of the TGF-β superfamily expressed in skeletal muscle. Deletion of myostatin leads to muscle hypertrophy and hyperplasia, which results in an almost doubled muscle mass in mice [10]. TGF-β1 and myostatin have common and contrastive features in their intracellular signaling pathways.

TGF-β1 functions by the active ligand binding to the TGF-β type I receptor (TβRI/ALK-5) or the activin like kinase-1 (ALK-1) receptor and the TGF-β type II receptor (TβRII, which triggers formation of a complex consisting of two TβRI and two TβRII subunits [1]. Following formation of the complex, TβRII subunits phosphorylate TβRI subunits at several serine and threonine residues within the receptor kinase domain, which leads to activation of primarily the SMAD pathway [1]. For myostatin signaling induction, the active myostatin ligand must bind to the activin receptor type IIA (ActR-IIA) or the activin receptor type IIB (ActR-IIB) and either the TβRI/ALK-5 receptor or the activin like kinase-4 (ALK-4) receptor [9]. This also leads to dimerization of the receptors, activation of serine-threonine kinase receptors, and downstream activation of the SMAD pathway. Therefore, both TGF-β1 and myostatin converge at the SMAD pathway. SMAD2 and SMAD3 are the main substrates for TGF-β receptors, referred to as receptor-regulated SMADs, or R-SMADs [11]. Further, SMAD4, also known as Co-SMAD, forms a complex with R-SMADs, and SMAD6 and SMAD7 are inhibitory SMADs (I-SMADs) that can interfere with SMAD interactions with the TGF-β receptors or other SMAD proteins [11].

The nucleocytoplasmic dynamics of these proteins are quite interesting, as SMAD proteins can undergo nuclear translocation without nuclear transport factors, or importins; instead, they can interact directly with nucleoporins [11]. However, in a basal state, R-SMADs (SMAD2/3) are mostly located in the cytosol, likely as a result of cytosolic SMAD-binding factors. Receptor-mediated phosphorylation of the R-SMADs results in a decreased affinity of R-SMADs for the SMAD-binding factors and an increased affinity for nucleoporins [11]. Likewise, SMAD4 shuttles between the cytosol and nucleus in a basal state, but receptor-mediated phosphorylation of the C-terminal of R-SMAD proteins creates a SMAD4 binding site, allowing the R-SMAD/Co-SMAD complex to enter and accumulate in the nucleus, where they act as transcription factors that regulate gene expression [1]. In skeletal muscle, these genes include the myogenic transcription factors, such as the muscle regulatory factors (MRFs) MyoD, Myf5, and myogenin [9]. In addition to this pathway, TGF-β ligands can also function by an alternative pathway involving mitogen-activated protein kinases (MAPKs). However, this pathway is much less well-documented [12].

3. TGF-β in Skeletal Muscle Myopathies

3.1. Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder resulting from a mutation of the dystrophin gene that leads to severe muscle degeneration as well as fibrosis of connective tissue [13]. While progress has been made in the understanding of DMD pathology, the underlying mechanisms of fibrosis within dystrophic muscle are still being studied. Several studies have shown that TGF-β1 levels are elevated in DMD patients in both plasma and muscle, and the expression of TGF-β1 is correlated with fibrosis (Table 1) [14,15]. Expression of TGF-β1 and CTGF have also been
shown to be upregulated specifically in the muscle cell sarcoplasm and myenteric interstitium of DMD patients compared to controls [16]. The expression levels of TGF-β1 and CTGF are significantly correlated with the degree of pathology and clinical severity of DMD [16]. Furthermore, based on a genome-wide mRNA profiling of DMD and control muscle, the TGF-β pathway is highly induced in patients with DMD compared to controls [17]. TGF-β1 is also upregulated in mdx muscle, the mouse model of DMD [18], and blunted TGF-β signaling in mdx mice leads to reduced levels of fibrosis [19,20].

3.2. Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that leads to loss of motoneurons, causing muscle atrophy and fibrosis [21]. An earlier study assessing TGF-β1 concentrations in serum and cerebrospinal fluid (CSF) of ALS patients found that TGF-β1 serum levels were significantly higher in terminal clinical status ALS patients than controls, and CSF concentrations of TGF-β1 were significantly positively correlated with the duration of ALS [22]. In muscle samples, TGF-β1 concentrations have also been shown to be increased compared to controls and to correlate with muscle strength [23]. Likewise, in G93A SOD1 mice, the mouse model of ALS, TGF-β1 increases with increased disease progression, implicating TGF-β1 as a biomarker of ALS in skeletal muscle [23]. Extensive fibrosis has been documented in skeletal muscle of G93A SOD1 mice, as these mice exhibit an increase in ECM components and increased amounts of the fibrotic proteins, fibronectin and collagen type I, at the perimysium and endomysium compared to control mice. This enhanced fibrosis is accompanied by an induction of TGF-β signaling, assessed by levels of phosphorylated, active SMAD3 [24]. Expression levels of TGF-β1 negatively correlate with lifespan in G93A SOD1 mice as well, and inhibition of TGF-β signaling extends survival [25].

3.3. Peripheral Artery Disease

Peripheral artery disease (PAD) is an atherosclerotic disease presenting as narrowing of the arteries of the lower extremities [26]. Notably, IRI is a main feature of PAD, as the lower extremity muscles of patients are under ischemia during activity, but experience reperfusion and re-oxygenation during rest. Constant effort-induced cycles of ischemia and reperfusion result in increased reactive oxygen species (ROS) formation and muscle oxidative damage, which leads to a myopathy in the affected leg muscles of patients that is characterized by myofiber degeneration and increased fibrosis [27].

Expression of TGF-β1 in PAD gastrocnemius muscle has been shown to be almost three times higher than controls [28]. Collagen deposition is also increased in PAD patients compared to controls and increases with advancing disease stage [28]. TGF-β1 expression also progressively increases with advancing disease stage and positively correlates with collagen density. Finally, TGF-β1 expression is associated with fibroblast accumulation in areas of collagen deposition, further supporting the idea of a TGF-β-induced progressive fibrosis in PAD skeletal muscle [28].

3.4. Marfan Syndrome

Marfan syndrome (MFS) is an inherited disorder that affects connective tissue, caused by mutations in FBN1, the gene encoding the ECM protein fibrillin-1 [29]. MFS is also associated with a severe myopathy, characterized by significant decreases in muscle mass, an inability to increase muscle mass, and an increase in skeletal muscle fibrosis [29]. Notably, circulating TGF-β1 concentrations have been shown to be elevated in patients with MFS compared with healthy individuals, and this has also been demonstrated in FBN1 mutant mice [30].
Table 1. Transforming growth factor-beta (TGF-β) in fibrosis-associated skeletal muscle myopathies.

| Study                          | Ref. | Myopathy | Source | Findings                                                                 |
|--------------------------------|------|----------|--------|--------------------------------------------------------------------------|
| Bernasconi et al., 1995        | [14] | DMD      | Muscle | • Higher TGF-β1 gene expression in DMD vs controls                       |
|                                |      |          |        | • TGF-β1 positively correlated with fibrosis                             |
| Ishitobi et al., 2000          | [15] | DMD      | Plasma | • Higher TGF-β1 concentrations in DMD vs controls                        |
| Chen et al., 2005              | [17] | DMD      | Muscle | • Strong induction of TGF-β1 pathway in symptomatic DMD patients vs controls by mRNA profiling |
| Song et al., 2017              | [16] | DMD      | Muscle | • Higher TGF-β1 protein expression in DMD vs controls                    |
|                                |      |          |        | • TGF-β1 positively correlated with degree of pathology and clinical severity |
| Ilzecka et al., 2002           | [22] | ALS      | Serum and CSF | • Higher serum TGF-β1 concentrations in terminal status ALS patients vs controls |
|                                |      |          |        | • CSF TGF-β1 positively correlated with duration of ALS                  |
| Si et al., 2015                | [23] | ALS      | Muscle | • Higher TGF-β1 gene and protein expression in ALS patients vs controls |
|                                |      |          |        | • TGF-β1 expression inversely correlated with muscle strength             |
| Ha et al., 2016                | [28] | PAD      | Muscle | • Higher TGF-β1 protein expression in PAD vs controls                    |
|                                |      |          |        | • TGF-β1 expression increased with advancing disease stage               |
|                                |      |          |        | • TGF-β1 expression correlated with fibrosis                             |
| Matt et al., 2009              | [30] | MFS      | Serum  | • Higher TGF-β1 expression in patients with MFS vs controls             |

DMD: Duchenne muscular dystrophy; ALS: amyotrophic lateral sclerosis; PAD: peripheral artery disease; CSF: cerebrospinal fluid; MFS: Marfan syndrome.

3.5. Aging-Associated Fibrosis

TGF-β1 is believed to also play a role in the muscle impairment and fibrosis that accompanies the aging process. During normal aging, muscle cells increase TGF-β1 levels, and transition to a more fibrotic phenotype [31]. Skeletal muscle gene expression of TGF-β1 has been shown to be higher in older versus younger adults [32]. Results of a global gene expression profiling suggested that aging muscle demonstrates an increase in expression for genes coding for TGF-β1 [33]. This phenomenon is believed to be due to one of two factors. First, the increased TGF-β1 expression may be a result of age-associated chronic inflammation, which drives fibroblast activation [33]. Second, this may reflect an attempt to repair accumulated tissue damage [33].

3.6. Other Myopathies

Increased TGF-β signaling has also been linked to several other acquired myopathies. For example, muscle atrophy induced by several conditions including hypoxia, microgravity, disuse, and cancer cachexia have all been associated with increased TGF-β1 and/or myostatin expression and activation [34–37]. Alterations in TGF-β signaling are also thought to be one of the molecular mechanisms that underlie sarcopenia, the age-related loss of skeletal muscle mass and function, due to the negative regulation of skeletal muscle development induced by TGF-β1 and myostatin [38]. Likewise, immobilization and injury, which are associated with acute muscle wasting, weakness, and muscle fibrosis, also show strong inductions of TGF-β [38]. For example, atrophic myofibers from patients with acute quadriplegic myopathy show increased stimulation of the TGF-β pathway [39]. Similarly, there is a significant increase in muscle fibrosis that contributes to muscle stiffness following many muscle injury models, such as rotator cuff tears. Interestingly, in a rat model for rotator cuff tears, it was shown that the significant increase in fibrosis in the rotator cuff muscle was associated with a concomitant increase in TGF-β1 gene and protein expression, further emphasizing the role of TGF-β in skeletal muscle pathology and impaired regeneration [40].

4. TGF-β-Induced Muscle Fibrosis: In-vitro and in-vivo Evidence

The earliest evidence demonstrating the involvement of TGF-β1 in skeletal muscle fibrosis comes from an in-vitro study by Li et al. [41]. Specifically, the C2C12 mouse myoblast cell line was cultured
with varying concentrations of TGF-β1. Expression of myogenic proteins including desmin, MyoD, and myogenin decreased significantly after TGF-β1 treatment compared to non-treated cells [41]. In contrast, non-treated cells expressed low levels of fibrotic proteins including α-smooth muscle actin (α-SMA), fibronectin, and vimentin, and treatment with TGF-β1 led to up-regulated fibrotic protein expression [41].

Similar results have also been reported in vivo. In a study by Mendias et al., mice treated with recombinant TGF-β1 displayed increased collagen I content of extensor digitorum longus (EDL) muscle ECM, increased procollagen Iα2 expression of the tibialis anterior (TA) muscle, and enhanced ECM accumulation compared to vehicle-treated mice [42]. The morphological changes in these mice were also accompanied by reduced contractile forces, as the maximum isometric force production of the EDL muscle was dramatically reduced in TGF-β1-treated mice [42]. In fact, compared to control muscle, TGF-β1-treated muscle showed a 75% reduction in maximum twitch force, a 66% reduction in specific twitch fore (normalized by cross-sectional area (CSA)), and an 89% increase in half-relaxation time [42]. Notably, this study indicated that TGF-β1 can directly induce muscle fibrosis and reductions in force-generating capacity independent of muscle injury or disease. In addition to fibrosis, TGF-β1-treated mice also exhibited significant muscle atrophy, indicated as reductions in muscle CSA of up to 38%. However, due to the extensive accumulation of collagen, there were no observed changes in whole muscle mass [42].

A study published a year later by Narola et al. suggested a dose-dependent response to TGF-β1 [43]. In the study, a tet-repressible muscle specific TGF-β1 mouse model (TRE-TGF-β1/ mCK-tTA) was used, with TGF-β1 transgene expression induced by discontinuation of doxycycline [43]. The onset of disease phenotype, assessed as loss in body weight with concomitant muscle weakness (measured by grip strength), greatly differed among the mice. Out of 20 TRE-TGF-β1/ mCK-tTAmice, 40% displayed disease phenotype within 2 weeks and were categorized as early onset (EO), and the remaining 60% were categorized as late onset (LO) (of which 30% displayed disease phenotype at 5-12 weeks and 30% did not show disease phenotype in the entire 15-week study period) [43]. The TGF-β1 protein expression in the skeletal muscle of LO mice was only 4 times greater than control mice, but there was a 234-fold elevation of TGF-β1 in the EO mice. Histochemical analysis of the quadricep muscles demonstrated that the mice over-expressing TGF-β1 (both EO and LO) displayed excessive collagen deposition, with collagen accumulation reaching almost 8-fold higher in the EO group than the control mice, and approximately 2-fold higher in the LO group compared to the control group. Myofiber size was also significantly reduced in both the EO and LO groups compared to controls. In addition, hindlimb muscle strength was significantly reduced in the EO group by 11.2% compared to the control mice [43].

5. Mechanisms

TGF-β is produced by different cell types, including T cells, macrophages, fibroblasts, and epithelial cells [44]. The TGF-β pathway can then lead to the activation of different cell lines, including resident fibroblasts, adult muscle-derived stem cells, fibrocytes, nerve-associated cells, and inflammatory or perivascular cells, into myofibroblasts, which are initiators of the fibrotic process [44]. Additionally, the recent discovery of an adult muscle progenitor population, the fibro-adipogenic progenitors (FAPs) has provided new insight into the cellular mechanisms of skeletal muscle fibrosis. Specifically, FAPs do not differentiate into muscle fibers, and rather only differentiate into adipocytes or myofibroblasts depending on the local environment [45]. Macrophages play an important role in this fate determination, as macrophages are associated with fibrosis in human DMD muscle as well as mdx mouse muscle [46, 47].

Following acute injury, for example, there is a large increase in FAPs to support muscle repair. Under normal conditions however, the FAP populations are returned to basal levels by apoptosis to prevent differentiation into fibroblasts which could increase fibrosis [48]. This apoptosis was shown by Lemos et al. to be induced by tumor necrosis alpha (TNF) that is expressed by pro-inflammatory macrophages [48]. Interestingly, they also showed that expression of TGF-β by anti-inflammatory macrophages blocks this TNF-driven apoptosis of FAPs and increases collagen expression and fibrosis. More recently, Juban et
al. also showed that pro-inflammatory macrophages can also produce latent TGF-β1, which is activated by enzymes provided by FAPs, ultimately leading to collagen production by fibroblasts in DMD [47]. It is also important to note that FAP cells are not confined as source of fibrosis in dystrophic muscle only. For example, Davies et al. demonstrated that in a mouse model of rotator cuff tear, TGF-β promoted muscle fibrosis by preventing FAP apoptosis as well [49]. Together, these studies point to the complicated cross-talk between both pro- and anti-inflammatory macrophages and FAPs that leads to increased fibrosis in primary skeletal muscle diseases as well as following conditions such as muscle injury.

5.1. Transcription Factors

Recent data has also provided new insight into the molecular mechanisms behind TGF-β-mediated muscle fibrosis (Figure 1). For example, studies have suggested that TGF-β may regulate fibrosis by modifying the expression of different transcription factors. One such transcription factor is scleraxis, which is expressed in fibroblasts and drives proliferation and type I collagen synthesis [50]. In a study by Mendias et al., treatment of mice with TGF-β led to increased levels of scleraxis and a concomitant increase in the activation of fibroblasts as well as collagen I content of the ECM in EDL muscles, suggesting that one way by which TGF-β may regulate fibrosis is by modifying scleraxis expression [42].

![Figure 1](image-url)
Furthermore, another transcription factor that has been implicated in muscle regeneration is Sharp-1. Following freeze injury, mice lacking Sharp-1 (Sharp-1\(^{-/-}\)) demonstrated enhanced quadriceps muscle fibrosis and an increase in the number of cells positive for \(\alpha\)-SMA compared to WT mice [51]. Sharp-1\(^{-/-}\) mice also demonstrated sustained elevations of TGF-\(\beta\) expression and signaling (phosphorylated SMAD2 and SMAD3) [51].

5.2. Inflammation

Fibrinogen, an acute phase protein that functions primarily to occlude blood vessels, also plays a role in tissue fibroblast proliferation [52]. Fibrinogen accumulation and deposits as well as TGF-\(\beta\) expression were shown to be increased in \(mdx\) mouse muscle [53]. Further, fibrinogen depletion reduced the expression of TGF-\(\beta\) and collagen I and attenuated fibrosis [53]. Fibrinogen-deficient mice also exhibited a reduction in the number of macrophages. In contrast, fibrinogen stimulation led to enhanced TGF-\(\beta\) expression by macrophages; however, this effect was lost when cells were treated with an interleukin 1 beta (IL-1\(\beta\)) neutralizing antibody. Together, these data suggest that fibrinogen may cause an inflammatory macrophage response resulting in the synthesis of IL-1\(\beta\), which leads to increased TGF-\(\beta\) expression by the macrophages [53].

Another inflammatory molecule that may play a role in muscular dystrophy-mediated fibrosis is osteopontin (OPN), a matricellular glycoprotein which functions as a cytokine and promotes migration and survival of immune cells [54]. Vetrone et al. first found that OPN is elevated in both the serum of \(mdx\) mice and muscle tissue of DMD patients [55]. They further studied the effect of OPN deletion in \(mdx\) mice, generating OPN-null, dystrophin-deficient, double-mutant mice (DMM). OPN deletion led to a reduction in neutrophils and natural killer T (NKT)-like cells and an increase in regulatory T cells (Tregs) in DMM muscles compared to muscles of \(mdx\) mice expressing OPN. These changes in inflammatory cells also were accompanied by a reduction in TGF-\(\beta\), which correlated with increased strength and reduced fibrosis [55]. This suggests that OPN may lead to an inflammatory cascade that results in greater intramuscular TGF-\(\beta\) signaling, promoting fibrosis.

5.3. Oxidative Stress

Angiotensin II (Ang-II) is implicated in skeletal muscle fibrotic disorders as well. Ang-II induces ECM proteins including type III collagen and fibronectin via signaling through the angiotensin II receptor type I (AT-1R) [56]. Incubation of C2C12 cells with Ang-II led to an increase in TGF-\(\beta\)1 and CTGF expression, but pre-incubation with the AT-1R blocker losartan abolished this effect [57]. Additionally, apocynin, an inhibitor of NADPH oxidase (NOX) activity, as well as the antioxidant N-acetyl cysteine (NAC) also prevented Ang-II-induced expression of TGF-\(\beta\)1 and CTGF, suggesting that Ang-II-induced expression of the pro-fibrotic factors involves NOX-induced ROS [57]. This is consistent with the results of another study in which inhibition of ROS production by NOX inhibitors led to decreased Ang-II dependent expression of the ECM proteins collagen-III and fibronectin as well as CTGF levels [58].

Enhanced oxidative stress from the endoplasmic reticulum (ER) is another pathological mechanism associated with myopathies and a fibrotic muscle phenotype. Pozzer et al. showed that in a mouse model of ER hyper-oxidation (over-expression of ER oxidoreductin 1 [ERO1], the main protein disulfide oxidase of the ER that generates hydrogen peroxide and knockout out selenoprotein N (SEPN1), an ER reductase), there was an up-regulation of the TGF-\(\beta\) pathway and TGF-\(\beta\) target genes, and a reduction in muscle tension [59]. In vitro, SEPN1 knock-down myoblasts also showed higher levels of phosphorylated (active) SMAD2 and SMAD3, as well as high levels of procollagen I, which was worsened by over-expression of ERO1 [59]. Decreased tissue ascorbic acid (antioxidant) levels were associated with enhanced TGF-\(\beta\) signaling in vivo, and ascorbic acid supplementation normalized TGF-\(\beta\) activity in SEPN1 knock-down myoblasts in vitro. Further, mice lacking L-Gulonolactone oxidase (Gulo KO mice), an enzyme required for ascorbic acid synthesis, showed a fibrotic phenotype...
in the gastrocnemius muscle, reduced muscle strength, and hyperactivity of the TGF-β pathway, which was attenuated with increasing doses of ascorbic acid treatment [59].

5.4. MicroRNAs

Finally, there is evidence that microRNAs (miRs) are also involved in TGF-β signaling. miRs are non-coding RNAs ~22 nucleotides long that suppress translation of target genes by binding to the 3’-untranslated regions (3’-UTRs) or by degrading target gene mRNAs [60]. Recently, miRs have been shown to play a role in myogenic regulation as powerful regulators of post-transcriptional gene regulation. For example, miR-29, which has been established as anti-fibrotic in pulmonary fibrosis [61], may also play a similar role in skeletal muscle. Notably, miR-29 levels are significantly reduced in muscle of patients with DMD and muscles of mdx mice [62,63]. Additionally, in-vitro, over-expression of miR-29 in C2C12 cells was shown to inhibit fibrogenic differentiation by suppressing the expression of Collagen 1A1, 1A2, and 3A1, while knock-down of miR-29 had the opposite effect [64]. Further, miR-29 has been shown to be under negative regulation by TGF-β, as treatment of C2C12 cells with TGF-β led to reduced expression and activity of miR-29, and reversed the miR-29-induced suppression on Collagens and α-SMA [64]. This finding suggests that miR-29 upregulation may be an effective strategy to treat muscle fibrosis, and in a preliminary study, administration of miR-29 by adeno-associated virus (AAV) delivery resulted in a favorable anti-fibrotic response in mdx mice [65].

Another miR, miR146a-5p (miR146), which has been shown to inhibit renal fibrosis [66], has recently also been studied for its potential to reduce skeletal muscle fibrosis after injury. Sun et al. showed that miR146 levels were significantly reduced after a mouse model of acute contusion of the TA muscle [67]. In vitro, transfection of C2C12 myoblasts with miR146 led to reduced gene and protein expression of SMA, vimentin, and type I collagen. Transfection of miR146 in vivo after acute contusion also reduced the expression of these pro-fibrotic markers [67]. Furthermore, SMAD4 was shown to be a direct target of miR146, and overexpression of SMAD4 attenuated the anti-fibrotic effect of miR146 in vivo. This suggests that miR146 may attenuate skeletal muscle fibrosis by downregulation of SMAD4 [67].

6. TGF-β-Targeted Treatments of Skeletal Muscle Fibrosis

Based on the role of TGF-β in skeletal muscle fibrosis, modulation of TGF-β signaling is believed to be a useful target for developing therapies for skeletal muscle myopathies (Table 2). Inhibition of TGF-β expression by small interfering RNA (siRNA) and short hairpin RNA (shRNA) as well as knockdown of the TGF-β receptor has been studied extensively in the treatment of pulmonary and liver fibrosis, but less in the context of skeletal muscle fibrosis [68-70]. More recently, however, antisense oligonucleotides (AOs), which are synthetic, short single-stranded oligodeoxynucleotides that can alter RNA and modify protein expression, have also been studied as anti-fibrotic agents [71]. These polymers are believed to be more attractive due to the transience of target knockdown and the approval of two AO drugs for the treatment of genetic diseases, including DMD [72]. For example, in the context of skeletal muscle fibrosis, intramuscular injection of AOs for ALK-5 (the TGF-β type-I receptor) decreased the expression of pro-fibrotic genes in mdx mice [73].

Furthermore, suramin, a TGF-β1 receptor antagonist, has been widely studied for its anti-fibrotic properties [74]. In mdx mice, suramin has been shown to significantly decrease fibrosis and reduce muscle fiber damage in TA and biceps brachii muscle. This attenuation was also accompanied by a reduction in forelimb muscle strength impairment [75]. Decorin, another inhibitor of TGF-β signaling, has also been shown to reduce pathology and α-SMA-positive cells in Sharp-1−/− mice [51].

Angiotensin-converting enzyme (ACE) inhibition has also been proposed as a therapeutic approach for fibrosis due to the aforementioned involvement of Ang-II and the AT-1R in the process. In one study, Morales et al. tested the effects of the ACE inhibitor enalapril on fibrosis in both sedentary and exercised (to exacerbate pathology and worsen disease progression) mdx mice [76]. Enalapril was shown to reduce skeletal muscle damage in both sedentary and exercised mdx mice as well as
improve gastrocnemius muscle strength. This was accompanied by a reduction in levels of the ECM proteins collagen III and fibronectin in the gastrocnemius. Interestingly, however, TGF-β1 expression and signaling were not significantly reduced after enalapril treatment, but rather CTGF expression was indeed reduced by enalapril [76]. Burks et al. also studied the effect of ACE inhibition on muscle remodeling, although in sarcopenic mice using losartan, an Ang-II receptor antagonist [77]. Specifically, mice treated with losartan prior to cardiotoxin administration in the TA muscle exhibited significantly less fibrotic tissue and greater functional recovery than placebo-treated mice. In this study, losartan was shown to blunt TGF-β signaling compared to placebo [77].

Based on the involvement of ROS in the fibrotic process, the transcription factor NF-E2-related factor 2 (Nrf2), which protects against oxidative stress by inducing antioxidant enzymes such as NAD(P)H quinone oxidoreductase 1 (NQO1) through the antioxidant response element (ARE) has been studied in the fibrosis of different organs, including hepatic fibrosis and renal fibrosis [78,79]. With respect to skeletal muscle, Sun et al. studied the effect of Nrf2 activation by sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables such as broccoli, in mdx mice [80]. The mdx mice treated with SFN demonstrated attenuated deposition of collagen in skeletal muscles, and levels of collagen I, fibronectin, and α-SMA were reduced [80]. SFN treatment also promoted ECM degradation by decreasing the inhibitors of TIMP-1 and plasminogen activator inhibitor-1 (PAI-1). In addition to the reduction in structural dystrophic features, SFN treatment also improved muscle function assessed by forelimb grip strength in mdx mice. These effects were likely mediated by Nrf2 activation, as SFN-treated mice exhibited increased expression of Nrf2 and the phase II detoxification enzymes heme oxygenase-1 (HO-1) and NQO1. SFN also strongly suppressed TGF-β1 expression and activation in mdx muscle, suggesting that SFN may lead to Nrf2-mediated suppression of TGF-β which attenuates muscle fibrosis [80]. Another compound, astaxanthin, has also been studied in a rat model of joint immobilization-induced muscle (soleus) fibrosis [81]. Astaxanthin, found mainly in marine organisms such as salmon, is an effective ROS scavenger with powerful antioxidant activity [82]. Following 14 days of immobilization, increased production of ROS and increased expression of TGF-β and α-SMA were observed, but these changes were attenuated by supplementation with 100 mg/kg/day of astaxanthin [81].

Table 2. TGF-β-targeted treatments.

| Study                     | Ref.   | Compound | Model       | Effect                              | Mechanism                              |
|---------------------------|--------|----------|-------------|-------------------------------------|----------------------------------------|
| Kemaladewi et al., 2014   | [73]   | ALK-5 AO | mdx mice    | Decreased fibrotic gene expression   | AO-mediated exon skipping               |
| Taniguti et al., 2011     | [75]   | Suramin  | mdx mice    | Decreased fibrosis                  | TGF-β1 receptor antagonist             |
| Acharjee et al., 2014     | [51]   | Decorin  | Sharp-1−/− mice | Reduced fibrotic pathology          | Inhibitor of TGF-β signaling          |
| Morales et al., 2013      | [76]   | Enalapril | mdx mice    | Reduced ECM proteins                 | ACE inhibitor                          |
| Burks et al., 2011        | [77]   | Losartan | sarcopenic mice | Reduced fibrotic tissue              | ACE inhibitor                          |
| Sun et al., 2016          | [80]   | Sulforaphane | mdx mice | Attenuated progression of fibrosis   | Nrf2 activator                         |
| Maezawa et al., 2017      | [81]   | Astaxanthin | Rat ankle joint | Decreased fibrosis                  | Antioxidant/ROS scavenger             |

ALK-5: TGF-β type I receptor; AO: antisense oligonucleotide; ECM: extracellular matrix; ACE: angiotensin-converting enzyme; Nrf2: NF-E2-related factor 2.

7. Conclusions

Enhanced activity of the TGF-β pathway plays a critical role in the pathogenesis of many different myopathies. TGF-β1 levels have been shown to be elevated in plasma, serum, and muscle tissue of patients with different skeletal muscle myopathies. Through different mechanisms, overexpression of TGF-β1 leads to the formation of fibrotic tissue in a process of dysregulated muscle regeneration. In vitro experiments have shown that culturing cells with TGF-β1 results in decreased myogenin protein expression and increased fibrotic protein expression [41,83]. In vivo experiments have demonstrated that TGF-β1 treatment results in increased collagen content of muscle as well as reduced fiber CSA [42,84].
Scleraxis and Sharp-1 have been identified as potential transcription factors that are upregulated by TGF-β signaling that drive fibrosis [42,85]. Furthermore, fibrinogen and osteopontin have been identified as proteins that may enhance TGF-β expression and fibrosis by induction of an inflammatory cascade [53,55]. Finally, ROS, derived from Ang-II, or NOX, have been implicated as sources that increase TGF-β and collagen expression [57,58]. Potential promising fibrosis therapeutics targeting TGF-β signaling include TGF-β1 and antagonists, ACE inhibitors, antioxidants, and Nrf2 activators.

One point worthy of noting is the fact that most fibrotic skeletal muscles also demonstrate myofiber atrophy. For example, in addition to the extensive fibrosis associated with DMD, ALS, and PAD, muscles from patients with these conditions also demonstrate significant muscle atrophy. Muscle unloading as a result of tenotomy also results in significant muscle fiber atrophy as well as fibrosis [86]. Therefore, it is possible that there is an association between muscle fiber atrophy and fibrosis. As mentioned in this review, TGF-β1 has also been shown to significantly reduce myofiber size. Therefore, it is possible that resetting muscles to altered length (as a result of myofiber atrophy) may initiate the fibrotic process in an attempt to restore or fix the length [44]. Future research should determine the atrophy-dependent and independent effects of TGF-β on skeletal muscle fibrosis and clarify the relationship between atrophy and fibrosis.

The timeline of changes in TGF-β signaling in different myopathies, as well as in the normal process of regulated muscle regeneration, remains unknown. Therefore, future studies will need to explore the specific timeline of TGF-β dysregulation to establish optimal therapeutic intervention. Additionally, most of the TGF-β-targeted treatments of skeletal muscle fibrosis have only been studied in cell culture and in animal models, but very limited numbers of human studies exist. Therefore, future research should include clinical trials of the promising compounds to establish their safety and efficacy. It is also possible that a multi-targeted approach may be optimal, so future studies should investigate the effects of a combination of targets. Another important question that remains to be answered is whether alterations in TGF-β signaling are functionally linked to muscle performance and functional outcome in patients suffering from myopathies characterized by elevations in TGF-β. However, an important consideration when designing these studies is the dual role of TGF-β as pro-fibrotic but also anti-inflammatory. One possible way to address this is by regionally restricted administration of the treatment so that the function is limited to only skeletal muscle tissue. Repressing TGF-β signaling may have therapeutic potential, but it is first important to further understand the intracellular mechanism of the pathway to address potential off-target effects.

Author Contributions: A.I., J.S.K., J.-S.K., R.S.S., W.T.B. and P.K. designed the review and completed the major parts of the article. A.I. and J.S.K. were responsible for compiling and reviewing the articles included in the review of literature. J.S.K. and P.K. were also responsible for proofing the article. A.I. created the artwork. A.I. and P.K. were accountable for final approval of the version. All authors read and approved this final article.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Massague, J. TGF β signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630. [CrossRef] [PubMed]
2. Leask, A.; Abraham, D.J. TGF-β signaling and the fibrotic response. FASEB J. 2004, 18, 816–827. [CrossRef]
3. Biernacka, A.; Dobaczewski, M.; Frangogiannis, N.G. TGF-β signaling in fibrosis. Growth Factors 2011, 29, 196–202. [CrossRef] [PubMed]
4. Kim, K.K.; Sheppard, D.; Chapman, H.A. TGF-β1 Signaling and Tissue Fibrosis. CSH Perspect. Biol. 2018. [CrossRef]
5. Meng, X.M.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-β: The master regulator of fibrosis. Nat. Rev. Nephrol. 2016, 12, 325–338. [CrossRef] [PubMed]
6. Branton, M.H.; Kopp, J.B. TGF-β and fibrosis. Microbes Infect. 1999, 1, 1349–1365. [CrossRef]
7. Gillies, A.R.; Chapman, M.A.; Bushong, E.A.; Deerinck, T.J.; Ellisman, M.H.; Lieber, R.L. High resolution three-dimensional reconstruction of fibrotic skeletal muscle extracellular matrix. *J. Physiol.* 2017, 595, 1159–1171. [CrossRef]

8. Kharraz, Y.; Guerra, J.; Pessina, P.; Serrano, A.L.; Munoz-Canoves, P. Understanding the process of fibrosis in Duchenne muscular dystrophy. *BioMed Res. Int.* 2014, 965631. [CrossRef]

9. Kollia, H.D.; McDermott, J.C. Transforming growth factor-beta and myostatin signaling in skeletal muscle. *J. Appl. Physiol. (1985)* 2008, 104, 579–587. [CrossRef] [PubMed]

10. McPherron, A.C.; Lawler, A.M.; Lee, S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature* 1997, 387, 83–90. [CrossRef]

11. Massague, J.; Seoane, J.; Wotton, D. Smad transcription factors. *Wiley Interdiscip. Rev. Dev. Biol.* 2013, 2, 47–63. [CrossRef] [PubMed]

12. Weiss, A.; Attisano, L. The TGFbeta superfamily signaling pathway. *Wiley Interdiscip. Rev. Dev. Biol.* 2013, 2, 47–63. [CrossRef] [PubMed]

13. Deconinck, N.; Dan, B. Pathophysiology of duchenne muscular dystrophy: Current hypotheses. *Pediatr. Neurol.* 2007, 36, 1–7. [CrossRef]

14. Bernasconi, P.; Torchiana, E.; Conflonieri, P.; Brugnoni, R.; Barresi, R.; Mora, M.; Cornelio, F.; Morandi, L.; Mantegazza, R. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. *J. Clin. Investig.* 1995, 96, 1137–1144. [CrossRef]

15. Ishitobi, M.; Hagino, K.; Zhao, Y.J.; Ohnuma, A.; Minato, J.; Yanagisawa, T.; Tanabe, M.; Kikuchi, M.; linuma, K. Elevated plasma levels of transforming growth factor β1 in patients with muscular dystrophy. *Neuroreport* 2000, 11, 4033–4035. [CrossRef] [PubMed]

16. Song, Y.; Yao, S.; Liu, Y.; Long, L.; Yang, H.; Li, Q.; Liang, J.; Li, X.; Lu, Y.; Zhu, H.; et al. Expression levels of TGF-beta1 and CTGF are associated with the severity of Duchenne muscular dystrophy. *Exp. Ther. Med.* 2017, 13, 1209–1214. [CrossRef]

17. Chen, Y.W.; Nagaraju, K.; Bakay, M.; Mcntyre, O.; Rawat, R.; Shi, R.; Hoffman, E.P. Early onset of inflammation and later involvement of TGF β in Duchenne muscular dystrophy. *Neurology* 2005, 65, 826–834. [CrossRef]

18. Zhou, L.; Porter, J.D.; Cheng, G.; Gong, B.; Hatala, D.A.; Merriam, A.P.; Zhou, X.; Rafael, J.A.; Kaminski, H.J. Temporal and spatial mRNA expression patterns of TGF-β1, 2, 3 and TβRI, II, III in skeletal muscles of mdx mice. *Neuromuscul. Disord.* 2006, 16, 32–38. [CrossRef]

19. Cohn, R.D.; van Erp, C.; Habashi, J.P.; Soleimani, A.A.; Klein, E.C.; Lisi, M.T.; Gamradt, M.; ap Rhys, C.M.; Holm, T.M.; Loeys, B.L.; et al. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. *Nat. Med.* 2007, 13, 204–210. [CrossRef]

20. Lorts, A.; Schwanekamp, J.A.; Baudino, T.A.; McNally, E.M.; Molkentin, J.D. Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-beta pathway. *Proc. Natl. Acad. Sci. USA* 2012, 109, 10978–10983. [CrossRef]

21. Hansarsa, O.; Rossi, D.; Berardinelli, A.; Cereda, C. Amyotrophic lateral sclerosis and skeletal muscle: An update. *Mol. Neurobiol.* 2014, 49, 984–990. [CrossRef] [PubMed]

22. Ilzecka, J.; Stelmasiak, Z.; Dobosz, B. Transforming growth factor-β1 (TGF-β1) in patients with amyotrophic lateral sclerosis. *Cytokine* 2002, 20, 239–243. [CrossRef]

23. Si, Y.; Kim, S.; Cui, X.Q.; Zheng, L.; Oh, S.J.; Anderson, T.; AlSharabati, M.; Kazamel, M.; Volpicelli-Daley, L.; Bamman, M.M.; et al. Transforming Growth Factor Beta (TGF-beta) Is a Muscle Biomarker of Disease Progression in ALS and Correlates with Smad Expression. *PLoS ONE* 2015, 10, e0138425. [CrossRef]

24. Gonzalez, D.; Contreras, O.; Rebolledo, D.L.; Espinoza, J.P.; van Zundert, B.; Brandon, E. ALS skeletal muscle shows increased TGF-β signaling, fibrosis and induction of fibro/adipogenic progenitor markers. *PLoS ONE* 2017, 12, e0177649. [CrossRef]

25. Endo, F.; Komine, O.; Fujimori-Tonou, N.; Katsuno, M.; Jin, S.; Watanabe, S.; Sobe, G.; Dezawa, M.; Wyss-Coray, T.; Yamanaka, K. Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. *Cell Rep.* 2015, 11, 592–604. [CrossRef]
27. Cluff, K.; Miserlis, D.; Naganathan, G.K.; Pipinos, I.I.; Koutakis, P.; Samil, A.; McComb, R.D.; Subbiah, J.; Casale, G.P. Morphometric analysis of gastrocnemius muscle biopsies from patients with peripheral arterial disease: Objective grading of muscle degeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305, R291–R299. [CrossRef]

28. Ha, D.M.; Carpenter, L.C.; Koutakis, P.; Swanson, S.A.; Zhu, Z.; Hanna, M.; DeSpiegelaere, H.K.; Pipinos, I.I.; Casale, G.P. Transforming growth factor-beta 1 produced by vascular smooth muscle cells predicts fibrosis in the gastrocnemius of patients with peripheral artery disease. J. Transl. Med. 2016, 14, 39. [CrossRef]

29. Dietz, H.C.; Cutting, G.R.; Pyeritz, R.E.; Maslen, C.L.; Sakai, L.Y.; Corson, G.M.; Puffenberger, E.G.; Hamosh, A.; Nanthakumar, E.J.; Curristin, S.M.; et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991, 352, 337–339. [CrossRef]

30. Matt, P.; Schoenhoff, F.; Habashi, J.; Holm, T.; Van Erp, C.; Loch, D.; Carlsson, O.D.; Grisswold, B.F.; Fu, Q.; De Backer, J.; et al. Circulating transforming growth factor-β in Marfan syndrome. Circulation 2009, 120, 526–532. [CrossRef]

31. Mann, C.J.; Ferdiguero, E.; Kharraz, Y.; Aguilar, S.; Pessina, P.; Serrano, A.L.; Munoz-Canoves, P. Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle 2011, 1, 21. [CrossRef]

32. Parker, L.; Caldow, M.K.; Watts, R.; Levinger, P.; Cameron-Smith, D.; Levinger, I. Age and sex differences in human skeletal muscle fibrosis markers and transforming growth factor-β signaling. Eur. J. Appl. Physiol. 2017, 117, 1463–1472. [CrossRef]

33. Zahn, J.M.; Sonu, R.; Vogel, H.; Crane, E.; Mazan-Mamczarz, K.; Rabkin, R.; Davis, R.W.; Becker, K.G.; Owen, A.B.; Kim, S.K. Transcriptional profiling of aging in human muscle reveals a common aging signature. PLoS Genet. 2006, 2, e115. [CrossRef]

34. Hayot, M.; Rodriguez, J.; Vernus, B.; Carnac, G.; Jean, E.; Allen, D.; Goret, L.; Obert, P.; Candau, R.; Bonnieu, A. Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli. Mol. Cell. Endocrinol. 2011, 332, 38–47. [CrossRef]

35. Lalani, R.; Bhasin, S.; Byhower, F.; Tarnuzzer, R.; Grant, M.; Shen, R.; Asa, S.; Ezzat, S.; Gonzalez-Cadavid, N.F. Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. J. Endocrinol. 2000, 167, 417–428. [CrossRef] [PubMed]

36. Hirose, T.; Nakazato, K.; Song, H.; Ishii, N. TGF-beta1 and TNF-alpha are involved in the transcription of type I collagen alpha2 gene in soleus muscle atrophied by mechanical unloading. J. Appl. Physiol. (1985) 2008, 104, 170–177. [CrossRef]

37. Costelli, P.; Muscaritoli, M.; Bonetto, A.; Penna, F.; Reffo, P.; Bossola, M.; Bonelli, G.; Doglietto, G.B.; Baccino, F.M.; Rossi Fanelli, F. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. 2008, 38, 531–538. [CrossRef] [PubMed]

38. Burks, T.N.; Cohn, R.D. Role of TGF-beta signaling in inherited and acquired myopathies. Skelet. Muscle 2011, 1, 19. [CrossRef]

39. Di Giovanni, S.; Molon, A.; Broccoli, A.; Melcon, G.; Mirabella, M.; Hoffman, E.P.; Servidei, S. Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann. Neurol. 2004, 55, 195–206. [CrossRef]

40. Liu, X.; Joshi, S.K.; Ravishankar, B.;aron, D.; Kim, H.T.; Feeley, B.T. Upregulation of transforming growth factor-beta signaling in a rat model of rotator cuff tears. J. Should. Elb. Surg. 2014, 23, 1709–1716. [CrossRef]

41. Li, Y.; Foster, W.; Deasy, B.M.; Chan, Y.S.; Prisk, V.; Tang, Y.; Cummings, J.; Huard, J. Transforming growth factor-beta 1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle—A key event in muscle fibrogenesis. Am. J. Pathol. 2004, 164, 1007–1019. [CrossRef]

42. Mendias, C.L.; Gumucio, J.P.; Davis, M.E.; Bromley, C.W.; Davis, C.S.; Brooks, S.V. Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and sclerosis. Muscle Nerve 2012, 45, 55–59. [CrossRef] [PubMed]

43. Narola, J.; Pandey, S.N.; Glick, A.; Chen, Y.W. Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS ONE 2013, 8, e79356. [CrossRef] [PubMed]

44. Lieber, R.L.; Ward, S.R. Cellular mechanisms of tissue fibrosis. 4. Structural and functional consequences of skeletal muscle fibrosis. Am. J. Physiol. Cell Physiol. 2013, 305, C241–C252. [CrossRef] [PubMed]

45. Joe, A.W.; Yi, L.; Natarajan, A.; Le Grand, F.; So, L.; Wang, J.; Rudnicki, M.A.; Rossi, F.M. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 2010, 12, 153–163. [CrossRef] [PubMed]
46. Tidball, J.G.; Wehling-Henricks, M. Shifts in macrophage cytokine production drive muscle fibrosis. *Nat. Med.* **2015**, *21*, 665–666. [CrossRef] [PubMed]

47. Juban, G.; Saclier, M.; Yacoub-Youssef, H.; Kernou, A.; Arnold, L.; Boisson, C.; Ben Larbi, S.; Magnan, M.; Cuvelier, S.; Theret, M.; et al. AMPK Activation Regulates LTBP4-Dependent TGF-beta1 Secretion by Pro-inflammatory Macrophages and Controls Fibrosis in Duchenne Muscular Dystrophy. *Cell Rep.* **2018**, *25*, 2163–2176. [CrossRef] [PubMed]

48. Lemos, D.R.; Babaeijandaghi, F.; Low, M.; Chang, C.K.; Lee, S.T.; Fiore, D.; Zhang, R.H.; Natarajan, A.; Nedosпасов, S.A.; Rossi, F.M. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. *Nat. Med.* **2015**, *21*, 786–794. [CrossRef]

49. Davies, M.R.; Liu, X.; Lee, L.; Laron, D.; Ning, A.Y.; Kim, H.T.; Feeley, B.T. TGF-beta Small Molecule Inhibitor SB431542 Reduces Rotator Cuff Muscle Fibrosis and Fatty Infiltration By Promoting Fibro/Adipogenic Progenitor Apoptosis. *PLoS ONE* **2016**, *11*, e0155486. [CrossRef]

50. Vidal, B.; Serrano, A.L.; Aranda, R.; Baeza-Raja, B.; Martinez de Lagran, M.; Lafuste, P.; Ruiz-Bonilla, V.; et al. Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta1-dependent macrophage activation pathway. *Genes Dev.* **2008**, *22*, 1747–1752. [CrossRef] [PubMed]

51. Lejard, V.; Brideau, G.; Blais, F.; Salingcarboriboon, R.; Wagner, G.; Roehrl, M.H.; Noda, M.; Duprez, D.; Houillier, P.; Rossert, J. Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts. *J. Biol. Chem.* **2007**, *282*, 17665–17675. [CrossRef]

52. Rybarczyk, B.J.; Lawrence, S.O.; Simpson-Haidaris, P.J. Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. *Blood* **2003**, *102*, 4035–4043. [CrossRef]

53. Hvidberg, T.; Skovholt, T.; Kaptein, H.; Nyberg, J.; Groop, L.H.; Hoeger, K.; et al. Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta1/alternative macrophage activation pathway. *Biochem. Biophys. Res. Commun.* **2016**, *474*, 150–155. [CrossRef] [PubMed]

54. Acharjee, S.; Chung, T.K.; Gopinadhan, S.; Shankar, S.R.; Wang, Y.; Liu, S.; Miceli, M.C.; Spencer, M.J. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. *J. Clin. Investig.* **2009**, *119*, 1583–1594. [CrossRef] [PubMed]

55. Lakshmanan, A.P.; Watanabe, K.; Thandavarayan, R.A.; Sari, F.R.; Harima, M.; Giridharan, V.V.; Soetikno, V.; Kodama, M.; Aizawa, Y. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-gamma signaling and skeletal muscle regeneration. *J. Cell Sci.* **2014**, *127*, 599–608. [CrossRef] [PubMed]

56. Vetrone, S.A.; Montecino-Rodriguez, E.; Kudryashova, E.; Kramerova, I.; Hoffman, E.P.; Liu, S.D.; Miceli, M.C.; Spencer, M.J. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. *J. Clin. Investig.* **2009**, *119*, 1583–1594. [CrossRef] [PubMed]

57. Morales, M.G.; Vazquez, Y.; Acuna, M.J.; Rivera, J.C.; Simon, F.; Salas, J.D.; Alvarez Ruf, J.; Brandan, E.; Cabello-Verrugio, C. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. *Int. J. Biochem. Cell Biol.* **2012**, *44*, 1993–2002. [CrossRef]

58. Cabello-Verrugio, C.; Acuna, M.J.; Morales, M.G.; Becerra, A.; Simon, E.; Brandan, E. Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells. *Biochem. Biophys. Res. Commun.* **2011**, *410*, 665–670. [CrossRef]

59. Pozzer, D.; Favellato, M.; Bolis, M.; Invernizzi, R.W.; Solagna, F.; Blauw, B.; Zito, E. Endoplasmic Reticulum Oxidative Stress Triggers TGF-beta-Dependent Muscle Dysfunction by Accelerating Ascorbic Acid Turnover. *Sci. Rep.* **2017**, *7*, 40993. [CrossRef]

60. Van Rooij, E. The art of microRNA research. *Circ. Res.* **2011**, *108*, 219–234. [CrossRef] [PubMed]

61. Cushing, L.; Kuang, P.; Lu, J. The role of miR-29 in pulmonary fibrosis. *Biochem. Cell Biol.* **2015**, *93*, 109–118. [CrossRef] [PubMed]

62. Van Rooij, E. The art of microRNA research. *Circ. Res.* **2011**, *108*, 219–234. [CrossRef] [PubMed]

63. Wang, L.; Zhou, L.; Jiang, P.; Lu, L.; Chen, X.; Lan, H.; Guttridge, D.C.; Sun, H.; Wang, H. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. *Mol. Ther. J. Am. Soc. Gene Ther.* **2012**, *20*, 1222–1233. [CrossRef] [PubMed]
64. Zhou, L.; Wang, L.J.; Lu, L.N.; Jiang, P.Y.; Sun, H.; Wang, H.T. Inhibition of miR-29 by TGF-beta-Smad3 Signaling through Dual Mechanisms Promotes Transdifferentiation of Mouse Myoblasts into Myofibroblasts. PLoS ONE 2012, 7, e33766. [CrossRef]

65. Heller, K.; Meadows, E.; Lewis, S.; Mendell, J.; Mendell, J.; Rodino-Klapac, L. MicroRNA-29 and Micro-Dystrophin Combinatorial Therapy Suppresses Fibrosis and Restores Function to mdx/utrn(+/−) Mice. Mol. Ther. 2016, 24, 8151. [CrossRef]

66. Morishita, Y.; Imai, T.; Yoshizawa, H.; Watanabe, M.; Ishibashi, K.; Muto, S.; Nagata, D. Delivery of microRNA-146a with polyethyleneimine nanoparticles inhibits renal fibrosis in vivo. Int. J. Nanomed. 2015, 10, 3475–3488. [CrossRef]

67. Sun, Y.Y.; Li, Y.; Wang, H.; Li, H.Y.; Liu, S.H.; Chen, J.W.; Ying, H. miR-146a-5p acts as a negative regulator of TGF-beta signaling in skeletal muscle after acute contusion. Acta Biochim. Biophys. Sin. 2017, 49, 628–634. [CrossRef]

68. Cheng, K.; Yang, N.; Mahato, R.I. TGF-beta1 gene silencing for treating liver fibrosis. Mol. Pharm. 2009, 6, 772–779. [CrossRef]

69. Lai, T.C.; Pociask, D.A.; Ferris, M.; Nguyen, H.T.; Miller, C.A.; 3rd, Brody, A.; Sullivan, D. Small interfering RNAs (siRNAs) targeting TGF-β1 mRNA suppress asbestos-induced expression of TGF-beta1 and CTGF in fibroblasts. J. Environ. Pathol. Toxicol. Oncol. 2009, 28, 109–119. [CrossRef]

70. Jain, M.; Lam, A.; Gottardi, C.J. Tissue-specific knockout/knockdown of type 2 TGF-beta receptor and protection against bleomycin injury/fibrosis. Am. J. Respir. Crit. Care Med. 2011, 184, 983. [CrossRef]

71. March, J.T.; Golshirazi, G.; Cernisova, V.; Carr, H.; Leong, Y.; Lu-Nguyen, N.; Popplewell, L.J. Targeting TGFbeta Signaling to Address Fibrosis Using Antisense Oligonucleotides. Biomedicines 2018, 6, 74. [CrossRef] [PubMed]

72. Rinaldi, C.; Wood, M.J.A. Antisense oligonucleotides: The next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 2018, 14, 9–21. [CrossRef]

73. Kemaladewi, D.U.; Pasteuning, S.; van der Meulen, J.W.; van Heiningen, S.H.; van Ommen, G.J.; Ten Dijk, P.; AartsmRUJla-Rus, A.; t Hoen, P.A.; Hoogaars, W.M. Targeting TGF-beta Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-beta Type I Receptor. Mol. Ther. Nucleic Acids 2014, 3, e156. [CrossRef]

74. Coffey, R.J., Jr.; Leof, E.B.; Shipley, G.D.; Moses, H.L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol. 1987, 132, 143–148. [CrossRef] [PubMed]

75. Taniguti, A.P.; Pertille, A.; Matsumura, C.Y.; Santo Neto, H.; Marques, M.J. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker. Muscle Nerve 2011, 43, 82–87. [CrossRef] [PubMed]

76. Morales, M.G.; Cabrera, D.; Cespedes, C.; Vio, C.P.; Vazquez, Y; Brandon, E.; Cabello-Verrugio, C. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell Tissue Res. 2013, 353, 173–187. [CrossRef]

77. Burks, T.N.; Andres-Mateos, E.; Marx, R.; Mejias, R.; Van Erp, C.; Simmers, J.L.; Walston, J.D.; Ward, C.W.; Cohn, R.D. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Transl. Med. 2011, 3, 82ra37. [CrossRef] [PubMed]

78. Oh, C.J.; Kim, J.Y.; Min, A.K.; Park, K.G.; Harris, R.A.; Kim, H.J.; Lee, I.K. Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. Free Radic. Biol. Med. 2012, 52, 671–682. [CrossRef] [PubMed]

79. Shin, D.H.; Park, H.M.; Jung, K.A.; Choi, H.G.; Kim, J.A.; Kim, D.D.; Kim, S.G.; Kang, K.W.; Ku, S.K.; Kessler, T.W.; et al. The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic. Biol. Med. 2010, 48, 1051–1063. [CrossRef]

80. Sun, C.; Li, S.; Li, D. Sulforaphane mitigates muscle fibrosis in mdx mice via Nrf2-mediated inhibition of TGF-beta/Smad signaling. J. Appl. Physiol. (1985) 2016, 120, 377–390. [CrossRef]

81. Maezawa, T.; Tanaka, M.; Kanazashi, M.; Maeshige, N.; Kondo, H.; Ishihara, A.; Fujino, H. Astaxanthin supplementation attenuates immobilization-induced skeletal muscle fibrosis via suppression of oxidative stress. J. Physiol. Sci. JPS 2017, 67, 603–611. [CrossRef] [PubMed]

82. Guerin, M.; Huntley, M.E.; Olaizola, M. Haematococcus astaxanthin: Applications for human health and nutrition. Trends Biotechnol. 2003, 21, 210–216. [CrossRef]
83. Li, Z.B.; Kollias, H.D.; Wagner, K.R. Myostatin directly regulates skeletal muscle fibrosis. *J. Biol. Chem.* **2008**, *283*, 19371–19378. [CrossRef]

84. Li, Z.B.; Zhang, J.Y.; Wagner, K.R. Inhibition of myostatin reverses muscle fibrosis through apoptosis. *J. Cell Sci.* **2012**, *125*, 3957–3965.

85. Azmi, S.; Ozog, A.; Taneja, R. Sharp-1/DEC2 inhibits skeletal muscle differentiation through repression of myogenic transcription factors. *J. Biol. Chem.* **2004**, *279*, 52643–52652. [CrossRef] [PubMed]

86. Abrams, R.A.; Tsai, A.M.; Watson, B.; Jamali, A.; Lieber, R.L. Skeletal muscle recovery after tenotomy and 7-day delayed muscle length restoration. *Muscle Nerve* **2000**, *23*, 707–714. [CrossRef]